Nevertheless, the incretin hormone GLP-1 and its analogs have garnered interest in the NASH context due to their potential therapeutic effects on metabolic dysfunction and liver pathology. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.